AARTI PHARMALABS
|
AARTI PHARMALABS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 19.27 | 30.06 | 23.93 | 21.35 | 4,890.04 |
| CEPS(Rs) | 30.78 | 39.64 | 32.01 | 28.25 | 6,574.79 |
| DPS(Rs) | 3.50 | 5.00 | 3.00 | 2.00 | - |
| Book NAV/Share(Rs) | 234.02 | 219.36 | 193.85 | 171.97 | 53,646.60 |
| Tax Rate(%) | 24.99 | 24.48 | 27.82 | 25.80 | 21.32 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 20.29 | 21.96 | 20.84 | 17.58 | 17.11 |
| EBIT Margin(%) | 15.38 | 18.32 | 17.15 | 14.49 | 13.95 |
| Pre Tax Margin(%) | 12.80 | 17.05 | 16.22 | 13.41 | 12.95 |
| PAT Margin (%) | 9.60 | 12.88 | 11.71 | 9.95 | 10.19 |
| Cash Profit Margin (%) | 15.34 | 16.99 | 15.66 | 13.16 | 13.70 |
| Performance Ratios | |||||
| ROA(%) | 5.47 | 9.93 | 8.99 | 9.03 | 11.98 |
| ROE(%) | 8.50 | 14.55 | 13.08 | 13.35 | 18.23 |
| ROCE(%) | 10.77 | 17.59 | 16.75 | 16.11 | 19.40 |
| Asset Turnover(x) | 0.57 | 0.77 | 0.77 | 0.91 | 1.18 |
| Sales/Fixed Asset(x) | 0.93 | 1.24 | 1.22 | 1.46 | 0.98 |
| Working Capital/Sales(x) | 3.96 | 3.18 | 2.84 | 3.46 | 2.68 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.08 | 0.80 | 0.82 | 0.68 | 1.02 |
| Receivable days | 116.23 | 94.46 | 95.50 | 77.57 | 114.57 |
| Inventory Days | 123.16 | 106.17 | 122.63 | 101.09 | 144.62 |
| Payable days | 133.87 | 111.22 | 128.34 | 86.45 | 61.41 |
| Valuation Parameters | |||||
| PER(x) | 30.58 | 24.91 | 18.18 | 12.86 | - |
| PCE(x) | 19.14 | 18.88 | 13.59 | 9.72 | - |
| Price/Book(x) | 2.52 | 3.41 | 2.24 | 1.60 | - |
| Yield(%) | 0.59 | 0.67 | 0.69 | 0.73 | - |
| EV/Net Sales(x) | 3.31 | 3.39 | 2.26 | 1.38 | 0.21 |
| EV/Core EBITDA(x) | 15.88 | 15.12 | 10.70 | 7.81 | 1.22 |
| EV/EBIT(x) | 21.51 | 18.50 | 13.16 | 9.55 | 1.53 |
| EV/CE(x) | 2.14 | 3.01 | 2.07 | 1.52 | 0.15 |
| M Cap / Sales | 2.94 | 3.21 | 2.13 | 1.28 | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | -13.98 | 14.17 | -4.76 | 62.11 | - |
| Core EBITDA Growth(%) | -20.13 | 21.37 | 13.52 | 64.41 | - |
| EBIT Growth(%) | -27.80 | 21.99 | 12.73 | 68.42 | - |
| PAT Growth(%) | -35.86 | 25.59 | 12.10 | 58.28 | - |
| EPS Growth(%) | -35.88 | 25.58 | 12.10 | -99.56 | - |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.32 | 0.20 | 0.15 | 0.14 | 0.25 |
| Current Ratio(x) | 1.49 | 2.02 | 1.94 | 1.94 | 1.77 |
| Quick Ratio(x) | 0.81 | 1.12 | 1.01 | 0.93 | 0.95 |
| Interest Cover(x) | 5.97 | 14.41 | 18.46 | 13.39 | 13.99 |
| Total Debt/Mcap(x) | 0.13 | 0.06 | 0.07 | 0.09 | - |
Compare Financial Ratios of peers of AARTI PHARMALABS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AARTI PHARMALABS | ₹7,858.2 Cr | -1.5% | 4.5% | 5.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹419,620.0 Cr | -0.2% | -5.1% | 8.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹239,714.0 Cr | -3.8% | -3.2% | 51.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹174,741.0 Cr | -1.7% | -7.7% | 29.9% | Stock Analytics | |
| CIPLA | ₹106,061.0 Cr | 0.6% | -3.8% | -11% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,339.0 Cr | 2.9% | 4.6% | 0.4% | Stock Analytics | |
AARTI PHARMALABS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AARTI PHARMALABS | -1.5% |
4.5% |
5.5% |
| SENSEX | 0.2% |
-2.8% |
-11.2% |
You may also like the below Video Courses
